A combination of two antioxidants (an SOD mimic and ascorbate) produces a pro-oxidative effect Forcing Escherichia coli to adapt via induction of oxyR regulon

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 4, 2011, Pages 329-340

  Batinić Haberle, Ines ^a   Rajić, Zrinka ^a,c   Benov, Ludmil ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KUWAIT UNIVERSITY   (Kuwait)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Adaptive response; AEOL10113; Antioxidants; E. coli; Mn porphyrins; OxyR regulon; Pro oxidants

Indexed keywords

ASCORBIC ACID; BACTERIAL ENZYME; BACTERIAL PROTEIN; CYTOTOXIC AGENT; GLUTATHIONE; HYDROGEN PEROXIDE; METALLOPORPHYRIN; OXYGEN; PEROXIDASE; PORPHYRIN DERIVATIVE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BIOACCUMULATION; BIOAVAILABILITY; CELL PROLIFERATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ESCHERICHIA COLI; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PROTEIN INDUCTION; REGULON; SIGNAL TRANSDUCTION;

EID: 79953772429     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011795677562     Document Type: Article

References (119)

1. Batinic-Haberle, I.; Reboucas, J. S.; Benov, L.; Spasojevic, I. In: Handbook of Porphyrin Science, volume 11; Kadish, K. M.; Smith, K. M.; Guillard, R., Eds.; World Scientific: Singapore 2010, vol. 11, 291-393.
2. Batinic-Haberle, I.; Rebouças, J. S.; Spasojevic, I. Superoxide dismutase mimics: Chemistry, pharmacology, and therapeutic potential. Antioxid. Redox Signal., 2010, 13, 877-918.
3. Ferrer-Sueta, G.; Vitturi, D.; Batinic-Haberle, I.; Fridovich, I.; Goldstein, S.; Czapski, G.; Radi, R. Reactions of manganese por-phyrins with peroxynitrite and carbonate radical anion. J. Biol. Chem., 2003, 278, 27432-27438.
4. Carnieri, N.; Harriman, A.; Porter, G. Photochemistry of manga-nese porphyrins. Part 6. Oxidation-reduction equilibria of manga-nese(III) porphyrins in aqueous solution. J. Chem. Soc. Dalton Trans., 1982, 931-938.
5. Spasojevic, I.; Batinic-Haberle, I.; Fridovich, I. Nitrosylation of manganese(II) tetrakis(N-ethylpyridinium-2-yl)porphyrin. Nitric Oxide, 2000, 4, 526-533.
6. Trostchansky, A.; Ferrer-Sueta, G.; Batthyány, C.; Botti, H.; Batinic-Haberle, I.; Radi, R.; Rubbo, H. Peroxynitrite flux-mediated LDL oxidation is inhibited by manganese porphyrins in the presence of uric acid. Free Radic. Biol. Med., 2003, 35, 1293-300.
7. Bloodsworth, A.; O'Donnell, V. B.; Batinic-Haberle, I.; Chumley, P. H.; Hurt, J. B.; Day, B. J.; Crow, J. P.; Freeman, B. A. Manganese-porphyrin reactions with lipids and lipoproteins. Free Radic. Biol. Med., 2000, 28, 1017-1029.
8. Gauter-Fleckenstein, B.; Fleckenstein, K.; Owzar, K.; Jian, C.; Batinic-Haberle, I.; Vujaskovic, Z. Comparison of two Mn porphy-rin-based mimics of superoxide-dismutase (SOD) in pulmonary ra-dioprotection. Free Radic. Biol. Med., 2008, 44, 982-989.
9. 5+ in mitigation and treatment of radiation-induced lung damage. Free Radic. Biol. Med., 2010, 48, 1034-1043.
10. Rabbani, Z.; Batinic-Haberle, I.; Anscher, M. S.; Huang, J.; Day, B. J.; Alexander, E.; Dewhirst, M. W.; Vujaskovic, Z. Long term administration of a small molecular weight catalytic metallopor-phyrin antioxidant AEOL10150 protects lungs from radiation-induced injury. Int. J. Radic. Oncol. Biol. Phys., 2007, 67, 573-580.
11. Rabbani, Z.; Salahuddin, F. K.; Yarmolenko, P.; Batinic-Haberle, I.; Trasher, B. A.; Gauter-Fleckenstein, B.; Dewhirst, M. W.; An-scher, M. S.; Vujaskovic, Z. Low molecular weight catalytic metal-loporphyrin antioxidant AEOL 10150 protects lungs from fractionated radiation. Free Radic. Res., 2007, 41, 1273-1282.
12. Zhao, Y.; Chaiswing, L.; Oberley, T. D.; Batinic-Haberle, I.; Clair, W.; Epstein, C. J., Clair, D. A mechanism-based antioxi-dant approach for the reduction of skin carcinogenesis. Cancer Res., 2005, 65, 1401-1405.
13. Moeller, B. J.; Batinic-Haberle, I.; Spasojevic, I.; Rabbani, Z. N.; Anscher, M. S.; Vujaskovic, Z.; Dewhirst, M. W. A manganese porphyrin superoxide dismutase mimetic enhances tumor radiore-sponsiveness. Int. J. Radiat. Oncol. Biol. Phys., 2005, 63, 545-552.
14. Moeller, B. J.; Cao, Y.; Li, C. Y.; Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of oxygenation, free radicals and stress granules. Cancer Cell, 2004, 5, 429-441.
15. 5+, via suppression of oxidative stress in a mouse model of breast tumor. Free Radic. Biol. Med., 2009, 47, 992-1004.
16. Sheng, H.; Yang, W.; Fukuda, S.; Tse, H. M.; Paschen, W.; Johnson, K.; Batinic-Haberle, I.; Crapo, J. D.; Pearlstein, R. D.; Pigan-elli, J.; Warner, D. S. Long-term neuroprotection from a potent re-dox-modulating metalloporphyrin in the rat. Free Radic. Biol. Med., 2009, 47, 917-923.
17. 5+. J. Pharmacol. Exp. Ther., 2010, submitted.
18. Batinic-Haberle, I.; Spasojevic, I.; Tse, H. M.; Tovmasyan, A.; Rajic, Z.; Clair, D. K.; Vujaskovic, Z.; Dewhirst, M. W.; Piganelli, J. D. Design of Mn porhyrins for treating oxidative stress injuries and their redox-based regulation of celluler transcriptional activities. Amino Acids, In press: doi: 10.1007/s726-010-0603-06; 2010.
19. Spasojevic, I.; Batinic-Haberle, I. SOD mimics. In: Pantopoulos, K.; Schipper, H., eds. Principles of Free Radical Biomedicine. Hauppauge New York: Nova Science Publishers, Inc; Hauppauge, NY, 2011, in press.
20. Batinic-Haberle, I.; Rajic, Z.; Tovmasyan, A.; Ye, X.; Leong, K. W.; Dewhirst, M. W.; Vujaskovic, Z.; Benov, L.; Spasojevic, I. Diverse functions of cationic Mn(III) substituted N-pyridylporphyrins, known as SOD mimics, Free Radic. Biol. Med., under revision, 2011.
21. Kos, I.; Benov, L.; Spasojevic, I.; Rebouças, J. S.; Batinic-Haberle, I. High lipophilicity of meta Mn(III) N-alkylpyridylporphyrin-based SOD mimics compensates for their lower antioxidant potency and makes them equally effective as ortho analogues in protecting E. coli. J. Med. Chem., 2009, 52, 7868-7872.
22. Murphy, M. P.; Smith, R. A. J. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 629-656.
23. Murphy, M. P. Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta., 2008, 177, 1028-1031.
24. 5+ targets mouse heart mitochondria. Free Radic. Biol. Med., 2007, 42, 1193-1200.
25. Tovmasyan, A.; Rajic, Z.; Spasojevic, I.; Reboucas, J. S.; Chen, X.; Salvemini, D.; Shengm H.; Warner, D. S.; Benov, L.; Batinic-Haberle, I. Methoxy-derivatization of alkyl chains increases the efficacy of cationic Mn porphyrins. Synthesis, characterization, SOD-like activity, and SOD-deficient E. coli study of meta Mn(III) N-methoxyalkylpyridylporphyrins. Dalton Trans., 2011, 40, 4111-4121.
26. Spasojevic, I.; Li, A. M.; Tovmasyan, A.; Rajic, Z.; Salvemini, D.; Clair, D.; Valentine, J. S.; Vujaskovic, Z.; Gralla, E. B.; Batinic-Haberle, I. Accumulation of porphyrin-based SOD mimics in mitochondria is proportional to their lipophilicity. S. cerevisiae study of ortho Mn(III) N-alkylpyridylporphyrins. Free Radic. Biol. Med., 2010, 49, S199.
27. Doyle, T.; Bryant, L.; Batinic-Haberle, I.; Little, J.; Cuzzocrea, S.; Masini, E.; Spasojevic, I.; Salvemini, D. Supraspinal inactivation of mitochondrial superoxide dismutase is a source of peroxynitrite in the development of morphine antinociceptive tolerance. Neuroscience, 2009,164, 702-710.
28. th International Conference on Porphyrins and Phthalocyanines, Albuquerque, USA, 2010.
29. Yu, L.; Drobyshevsky, A.; Derrick, M.; Luo, K.; Batinic-Haberle, I.; Tan, S. Effect of Mn porphyrins and antioxidants on MRI predictors and behavior in an animal model of cerebral palsy. Free Radic. Biol. Med., 2010, 49, S159.
30. Harrison, F. R.; May, J. M. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic. Biol. Med., 2009, 46, 719-730.
31. th ed.; Oxford University Press: Nex York, 2007.
32. Williams, N. H.; Yandell, J. K. Outer-sphere electron-transfer reactions of ascorbate anions. Austr. J. Chem., 1982, 35, 1133-1144.
33. Veraxx, J.; Buc Calderon, P. The controversial place of vitamin C in cancer treatment. Biochem. Pharmacol, 2008, 76, 1644-1652.
34. Padayatty, S. J.; Levine, M. New insights into the physiology and pharmacology of vitamin C. Can. Med. Assoc. J., 2001, 164, 353-355.
35. Corti, A.; Casini, A. F.; Pompella, A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch. Biochem. Biophys., 2010, 500, 107-115.
36. + dependent L-ascorbic acid transporters. Nature, 1999, 399, 70-75.
37. Agus, D. B.; Vera, J. C; Golde, D. W. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res., 1999, 59, 4555-4558.
38. Corti, A.; Raggi, C; Franzini, M.; Paolicchi, A.; Pompella, A.; Casini, A. F. Plasma membrane y-glutamyltransferase activity facilitates the uptake of vitamin C in melanoma cells. Free Radic. Biol. Med., 2004, 37, 1906-1915.
39. Wilson, J. X. The physiological role of dehydroascorbic acid. FEBS Lett, 2002, 527, 5-9.
40. Verrax, J.; Curi Pedrosa, R.; Beck, R.; Dejeans, N.; Taper, H.; Buc Calderon, P. In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr. Med. Chem., 2009, 16, 1821-1830.
41. Agus, D.; Vera, J.; Golde, D. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res., 1999, 59, 4555-4558.
42. Landolt, H.; Langemann, H.; Probst, A.; Gratzl, O. Levels of water-soluble antioxidants in astrocytoma and in adjacent tumor-free tissue. J. Neurooncol, 1994, 21, 127-133.
43. Kuiper, C; Molenaar, I. G. M.; Dachs, G. U.; Currie, M. J.; Sykes, P. H.; Vissers, M. C. M. Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res., 2010, 70, 5749-5758.
44. Chen, Q.; Espey, M. G.; Krishna, M. C.; Mitchell, J. B.; Corpe, C. P.; Buettner, G. R.; Shacter, E.; Levine, M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad. Sci. USA, 2005, 102, 13604-13609.
45. Chen, Q.; Espey, M. G.; Sun, A. Y.; Lee, J.-H.; Krishna, M. C.; Shacter, E.; Choyke, P. L.; Pooput, C.; Kirk, K. L.; Buettner, G. R.; Levine, M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl. Acad. Sci. USA, 2007, 104, 8749-8754.
46. Chen, Q.; Espey, M. G.; Sun, A. Y.; Pooput, C.; Kirk, K. L.; Krishna, M. C.; Khosh, D. B.; Drisko, J.; Levine, M. Pharma-cologic doses of ascorbate act as prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl. Acad. Sci. USA, 2008, 105, 11105-11109.
47. Levine, M. Conry-Cantilena, C.; Wang, Y.; Welch, R. W.; Washko, P. W.; Dhariwal, K. R.; Park, J. B.; Lazarev, A.; Graum-lich, J. F.; King, J.; Cantilena, L. R. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. USA, 1996, 93, 3704-3709.
48. Levine, M.; Wang, Y.; Padayatty, S.; Morrow, J. A new recommended dietary allowance of vitamin C for healthy young women. Proc. Natl. Acad. Sci. USA, 2001, 98, 9842-9846.
49. Veraxx, J.; Buc Calderon, P. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic. Biol. Med., 2009, 47, 32-40.
50. Verrax, J.; Stockis, J.; Tison, A.; Taper, H.; Calderon, P. Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. Biochem. Pharmacol., 2006, 72, 671-680.
51. Verrax, J.; Vanbever, S.; Stockis, J.; Taper, H.; Calderon, P. Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leu-kemic cells. Int. J. Cancer., 2007, 120, 1192-1197.
52. Taper, H.; de Gerlache, J.; Lans, M.; Roberfroid, M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int. J. Cancer., 1987, 40, 575-579.
53. Kassouf, W.; Highshaw, R.; Nelkin, G.; Dinney, C.; Kamat, A. Vitamins C and K3 sensitize human urothelial tumors to gemcit-abine. J. Urol., 2006, 176, 1642-1647.
54. Abdel-Latif, M.; Raouf, A.; Sabra, K.; Kelleher, D.; Reynolds, J. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J. Chemother., 2005, 17, 539-549.
55. Bahlis, N.; McCafferty-Grad, J.; Jordan-McMurry, I.; Neil, J.; Reis, I.; Kharfan-Dabaja, M.; Eckman, J.; Goodman, M.; Fernandez, H.; Boise, L.; Lee, K. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer. Res., 2002, 8, 3658-3668.
56. Dai, J.; Weinberg, R.; Waxman, S.; Jing, Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 1999, 93, 268-277.
57. Grad, J.; Bahlis, N.; Reis, I.; Oshiro, M.; Dalton, W.; Boise, L. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 2001, 98, 805-813.
58. Berenson, J.; Boccia, R.; Siegel, D.; Bozdech, M.; Bessudo, A.; Stadtmauer, E.; Talisman Pomeroy, J.; Steis, R.; Flam, M.; Lutzky, J.; Jilani, S.; Volk, J.; Wong, S.; Moss, R.; Patel, R.; Ferretti, D.; Russell, K.; Louie, R.; Yeh, H.; Swift, R. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br. J. Haematol., 2006, 135, 174-183.
59. Berenson, J.; Matous, J.; Swift, R.; Mapes, R.; Morrison, B.; Yeh, H. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res., 2007, 13, 1762-1768.
60. Prasad, K. N.; Sinha, P. K.; Ramanujam, M.; Sakamoto, A. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc. Natl. Acad. Sci. USA, 1979, 76, 829-832.
61. Kurbacher, C. M.; Wagner, U.; Kolster, B.; Andreotti, P. E.; Krebs, D.; Bruckner, H. W. Ascorbic acid (vitamin C) improves the anti-neoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett., 1996, 103, 183-189.
62. Song, E. J.; Yang, V. C.; Chiang, C. D.; Chao, C. C. Potentiation of growth inhibition due to vincristine by ascorbic acid in a resistant human non-small cell lung cancer cell line. Eur. J. Pharmacol., 1995, 292, 119-125.
63. Frömberg, A.; Gutsch, D.; Schilze, D.; Vollbracht, C.; Weiss, G.; Czubayko, F.; Aigner, A. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cy-tostatic drugs. Cancer Chemother. Pharmacol., 2010, in press. DOI: 10.1007/s00280-010-1418-6.
64. Nagy, B.; Mucsi, I.; Molnar, J.; Varga, A.; Thurzo, L. Chemosensi-tizing effect of vitamin C in combination with 5-fluorouracil in vitro. In vivo, 2003, 17, 289-292.
65. Batinic-Haberle, I.; Spasojevic, I.; Fridovich, I. Tetrahydrobiop-terin rapidly reduces the SOD mimic Mn(III) ortho-tetrakis(N-ethylpyridinium-2-yl)porphyrin. Free Radic. Biol. Med., 2004, 37, 367-374.
66. Ferrer-Sueta, G.; Quijano, C.; Alvarez, B.; Radi, R. Reactions of manganese porphyrins and manganese-superoxide dismutase with peroxynitrite. Methods Enzymol., 2002, 349, 23-37.
67. Ferrer-Sueta, G.; Batinic-Haberle, I.; Spasojevic, I.; Fridovich, I.; Radi, R. Catalytic scavenging of peroxynitrite by isomeric Mn(III) N-methylpyridylporphyrins in the presence of reductants. Chem. Res. Toxicol., 1999, 12, 442-449.
68. Ferrer-Sueta, G.; Hannibal, L.; Batinic-Haberle, I.; Radi, R. Reduction of manganese porphyrins by flavoenzymes and submitochon-drial particles and the catalytic redox cycle of peroxynitrite. Free Radic. Biol. Med., 2006, 41, 503-512.
69. 5+ in the treatment of brain tumors. Anticancer Agents Med. Chem., 2011, 11, 202-212.
70. .- dismu-tation. J. Chem. Soc. Dalton Trans., 2002, 2689-2696.
71. .- dismutation. Mn(III) methoxyethylpyridyl-and methoxyethylimidazolylporphyrins. J. Chem. Soc. Dalton Trans., 2004, 1696-1702.
72. Batinic-Haberle, I.; Spasojevic, I.; Hambright, P.; Benov, L.; Crumbliss, A. L.; Fridovich, I. The relationship between redox potentials, proton dissociation constants of pyrrolic nitrogens, and in vitro and in vivo superoxide dismutase activities of manganese(III) and iron(III) cationic and anionic porphyrins. Inorg. Chem., 1999, 38, 4011-4022.
73. Spasojevic, I.; Colvin, O. M.; Warshany, K. R.; Batinic-Haberle, I. New approach to the activation of anti-cancer pro-drug by metal-loporphyrin-based cytochrome P450 mimics in all-aqueous biologically relevant system. J. Inorg. Biochem., 2006, 100, 1897-1902.
74. Forman, H. J.; Maiorino, M.; Ursini, F. Signaling functions of reactive oxygen species. Biochemistry, 2010, 49, 835-842.
75. Kim, A.; Joseph, S.; Khan, A.; Epstein, C. J.; Sobel, R.; Huang, T.-T. Enhanced expression of mitochondrial superoxide dismutase leads to prolonged in vivo cell cycle progression and up-regulation of mitochondrial thioredoxin. Free Radic. Biol. Med., 2010, 48, 1501-1512.
76. Crow, J. Catalytic antioxidants to treat amyotrophic lateral sclerosis. Expert Opin. Invest. Drugs, 2006, 15, 1383-1392.
77. Crow, J. P.; Calinasan, N. Y.; Chen, J.; Hill, J. L.; Beal, M. F. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol., 2005, 58, 258-265.
78. Crow, J. P. In Inorganic Chemistry; Doctrow, S. R.; McMurry, T. J.; Sessler, S. J.; Eds.; American Chemical Society: Washington, DC, 2005.
79. Arambula, J. F.; Preihs, C; Brothwick, D.; Magda, D.; Sessler, J. L. Texaphyrins: tumor localizing redox active expanded porphyrins. Anticancer Agents Med. Chem., 2011,11, 222-232.
80. Jaramillo, M. C; Frye, J. B.; Crapo, J. D.; Briehl, M. M.; Tome, M. E. Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells. Cancer Res., 2009, 69, 5450-5457.
81. Jaramillo, M. C; Briehl, M. M.; Tome, M. E. Manganese porphyrin glutathionylates the p65 subunit of NF-kB to potentiate gluco-corticoid-induced apoptosis in lymphoma. Free Radic. Biol. Med., 2010, 49, S63.
82. Ye, X.; Fels, D.; Dedeugd, C; Dewhirst, M. W.; Leong, K.; Batinic-Haberle, I. The in vitro cytotoxic effects of Mn(III) al-kylpyridylporphyrin/ascorbate system on four tumor cell lines. Free Radic. Biol. Med., 2009, 47, S136.
83. Tian, J.; Peehl, D. M.; Knox, S. J. Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through Fenton chemistry. Cancer Biother. Radiopharm., 2010, 25, 439-447.
84. Buettner, G. R.; Jurkiewicz, B. A. Catalytic metals, ascorbate and free radicals: Combinations to avoid. Radiat. Res., 1996, 145, 532-541.
85. Nepomuceno, M. F.; Tabak, M.; Vercesi, A. E. Opposite effects of Mn(III) and Fe(III) forms of meso-tetrakis(4-N-methyl pyridinium-yl) porphyrins on isolated rat liver mitochondria. J. Bioenerg. Biomembr., 2002, 34, 41-47.
86. Touati, D.; Jacques, M.; Tardat, B.; Bouchard, L.; Despied, S. Lethal oxidative damage and mutagenesis are generated by iron in Afur mutants of Escherichia coli: Protective role of superoxide dismutase. J. Bacteriol, 1995,177, 2305-2314.
87. Tsaneva, I. R.; Weiss, B. SoxR, a locus governing a superoxide response regulon in Escherichia coli K-12. J. Bacteriol, 1990,172, 4197-4205.
88. Maniatis, T.; Fritsch, E. F.; Sambrook, J. Molecular Cloning: A Laboratory Manual; Cold Spring Harbor: New York, 1982.
89. Faulkner, K. M.; Liochev, S. I.; Fridovich, I. Stable Mn(III) porphyrins mimic superoxide dismutase in vitro and substitute for it in vivo. J. Biol. Chem., 1994, 269, 23471-23476.
90. McCord, J. M.; Fridovich, I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem., 1969, 244, 6049-6055.
91. Liochev, S. I.; Hausladen, A.; Fridovich, I. Nitroreductase A is regulated as a member of the soxRS regulon of Escherichia coli. Proc. Natl. Acad. Sci. USA, 1999, 96, 3537-3539.
92. Liochev, S. I.; Fridovich, I. Fumarase C, the stable fumarase of Escherichia coli, is controlled by the soxRS regulon. Proc. Natl. Acad. Sci. USA, 1992, 89, 5892-5896.
93. Hassan, H. M.; Fridovich, I. Regulation of the synthesis of catalase and peroxidase in Escherichia coli. J. Biol. Chem., 1978, 253, 6445-6450.
94. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 1951, 193, 265-275.
95. •- disproportionation. Inorg. Chem., 2002, 41, 5874-5881.
96. Kos, I.; Rebouças, J. S.; DeFreitas-Silva, G.; Salvemini, D.; Vujaskovic, Z.; Dewhirst, M. W.; Spasojevic, I.; Batinic-Haberle, I. The effect of lipophilicity of porphyrin-based antioxidants. Comparison of ortho and meta isomers of Mn(III) N-alkylpyridyl-porphyrins. Free Radic. Biol. Med., 2009, 47, 72-78.
97. Vance, C. K.; Miller, A. F. A simple proposal that can explain the inactivity of metal-substituted superoxide dismutases. J. Am. Chem. Soc, 1998,120, 461-467.
98. Goldstein, S.; Fridovich, I.; Czapski, G. Kinetic properties of Cu,Zn-superoxide dismutase as a function of metal content-Order restored. Free Radic. Biol. Med., 2006, 41, 937-941.
99. Reboucas, J. S.; DeFreitas-Silva, G.; Idemori, Y. M.; Spasojevic, I.; Benov, L.; Batinic-Haberle, I; The impact of electrostatics in redox modulation of oxidative stress by Mn porphyrins. Protection of SOD-deficient E. coli via alternative mechanism where Mn porphyrin acts as a Mn-carrier. Free Radic. Biol. Med. 2008, 45, 201-210.
100. Spasojevic, I.; Batinic-Haberle, I.; Reboucas, J. S.; Idemori, Y. M.; Fridovich, I. Electrostatic contribution in the catalysis of O2 dis-mutation by superoxide dismutase mimics. J. Biol. Chem., 2003, 278, 6831-6837.
101. Campos, E.; Montella, C; Garces, F.; Baldoma, L.; Aguilar, J.; Badia, J. Aerobic L-ascorbate metabolism and associated oxidative stress in Escherichia coli. Microbiology, 2007,153, 3399-3408.
102. Imlay, J. A. Cellular defenses against superoxide and hydrogen peroxide. Ann. Rev. Biochem., 2008, 77, 755-776.
103. Fuentes, A. M.; Amábile-Cuevas, C. F. Antioxidant vitamins C and E affect the superoxide-mediated induction of the soxRS regulon of Escherichia coli. Microbiology, 1998,144, 1731-1736.
104. Djaman, O.; Outten, F. W.; Imlay, J. A. Repair of oxidized iron-sulfur clusters in Escherichia coli. J. Biol. Chem., 2004, 279, 44590-44599.
105. McCormick, M. L.; Buettner, G. R.; Britigan, B. E. Endogenous superoxide dismutase levels regulate iron-dependent hydroxyl radical formation in Escherichia coli exposed to hydrogen peroxide. J. Bacteriol, 1998,180, 622-625.
106. Liochev, S.; Fridovich, I. A cationic manganic porphyrin inhibits uptake of paraquat by Escherichia coli. Arch. Biochem. Biophys., 1995, 321, 271-275.
107. Kobayashi, N.; Saiki, H.; Osa, T. Catalytic electroreduction of molecular oxygen using [5,10,15,20-tetrakis-(1-methylpyridinium-4-yl)porphinato]manganese. Chem. Lett., 1985,14, 1917-1920.
108. Li, X.; Cobb, C. E.; Hill, K. E.; Burk, R. F.; May, J. M. Mitochondrial uptake and recycling of ascorbic acid. Arch. Biochem. Biophys., 2001, 387, 143-153.
109. Rozanova, N.; Zhang, J. Z.; Heck, D. E. Catalytic therapy of cancer with porphyrins and ascorbate. Cancer Lett., 2007, 252, 216-224.
110. Du, J.; Martin, S. M.; Levine, M.; Wagner, B. A.; Buettner, G. R.; Wang, S. H.; Taghiyev, A. F.; Du, C; Knudson, C. M.; Cullen, J. J. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res., 2010, 16, 509-520.
111. Takemura, Y.; Satoh, M.; Satoh, K.; Hamada, H.; Sekido, Y.; Kubota, S. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem. Biophys. Res. Comm., 2010, 394, 249-253.
112. Ohno, S.; Ohno, Y.; Suzuki, N.; Soma, G. I.; Inoue, M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res., 2009, 29, 809-816.
113. Tse, H. M.; Milton, M. J.; Piganelli, J. D. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic. Biol. Med., 2004, 36, 233-247.
114. Reuter, S.; Gupta, S. C; Chaturvedi, M. M.; Aggrawal, B. B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med., 2010, 49, 1603-1616.
115. Grek, C. L.; Tew, K. D. Redox metabolism and malignancy. Curr. Opin. Pharmacol, 2010,10, 362-368.
116. 2 and inflammatory cytokine production. PLoS One, 2008, 3, e3367.
117. Singh, M.; Spoelstra, N. S.; Jean, A.; Howe, E.; Torkko, K. C; Clark, H. R.; Darling, D. S.; Shroyer, K. R.; Horwitz K. B.; Broad-dus, R. R.; Richer, J. K. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod. Pathol, 2008, 21, 912-923.
118. Mills, C. N.; Joshi, S. S.; Niles, R. M.; Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol. Cancer., 2009, 8,104.
119. Qiao, Q.; Nozaki, Y.; Sakoe, K.; Komatsu, N.; Kirito, K. NF-kB mediates aberrant activation of HIF-1 in malignant lymphoma. Exp. Hematol, 2010, 38, 1199-208.